

Qiming Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8720827/publications.pdf>

Version: 2024-02-01

62
papers

2,251
citations

471509

17
h-index

254184

43
g-index

63
all docs

63
docs citations

63
times ranked

2884
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2018, 4, 1569.	7.1	388
2	Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel. <i>JAMA Oncology</i> , 2019, 5, 696.	7.1	380
3	Emerging therapies for small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 47.	17.0	273
4	MEK inhibitors for the treatment of non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2021, 14, 1.	17.0	224
5	MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 63.	17.0	181
6	Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2022, 23, 739-747.	10.7	111
7	Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study. <i>British Journal of Cancer</i> , 2021, 125, 366-371.	6.4	71
8	Cholesterol reduces the sensitivity to platinum-based chemotherapy via upregulating ABCG2 in lung adenocarcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2015, 457, 614-620.	2.1	37
9	Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib. <i>Cancer Research</i> , 2021, 81, 4822-4834.	0.9	29
10	The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTERO303 trial. <i>Translational Lung Cancer Research</i> , 2019, 8, 575-583.	2.8	27
11	MicroRNAs: novel biomarkers for lung cancer diagnosis, prediction and treatment. <i>Experimental Biology and Medicine</i> , 2012, 237, 227-235.	2.4	26
12	Loss of cell adhesion molecule L1 like promotes tumor growth and metastasis in esophageal squamous cell carcinoma. <i>Oncogene</i> , 2019, 38, 3119-3133.	5.9	25
13	Clinical significance of the expression of miRNA-21, miRNA-31 and miRNA-let7 in patients with lung cancer. <i>Saudi Journal of Biological Sciences</i> , 2019, 26, 777-781.	3.8	24
14	ATF2 inhibits anti-tumor effects of BET inhibitor in a negative feedback manner by attenuating ferroptosis. <i>Biochemical and Biophysical Research Communications</i> , 2021, 558, 216-223.	2.1	23
15	Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer. <i>Biomarker Research</i> , 2019, 7, 27.	6.8	22
16	Polymorphisms at the microRNA binding-site of the stem cell marker gene <i>CD133</i> modify susceptibility to and survival of gastric cancer. <i>Molecular Carcinogenesis</i> , 2015, 54, 449-458.	2.7	20
17	Poor prognosis disclosure preference in cancer patient-caregiver dyads and its association with their quality of life and perceived stress: a cross-sectional survey in mainland China. <i>Psycho-Oncology</i> , 2016, 25, 1099-1105.	2.3	20
18	Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTERO303 trial. <i>Cancer Medicine</i> , 2020, 9, 2621-2630.	2.8	19

#	ARTICLE	IF	CITATIONS
19	Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors. <i>Molecular Cancer Research</i> , 2021, 19, 1622-1634.	3.4	19
20	SEMA3B improves the survival of patients with esophageal squamous cell carcinoma by upregulating p53 and p21. <i>Oncology Reports</i> , 2016, 36, 900-908.	2.6	18
21	Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 235-240.	2.5	18
22	Depression induces poor prognosis associates with the down-regulation brain derived neurotrophic factor of serum in advanced small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 85975-85986.	1.8	17
23	Upregulation of IBSP Expression Predicts Poor Prognosis in Patients With Esophageal Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 1117.	2.8	16
24	Macrophages confer resistance to BET inhibition in triple-negative breast cancer by upregulating IKBKE. <i>Biochemical Pharmacology</i> , 2020, 180, 114126.	4.4	16
25	Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis. <i>Theranostics</i> , 2021, 11, 3964-3980.	10.0	15
26	Potentially functional variants of HBEGF and ITPR3 in GnRH signaling pathway genes predict survival of non-small cell lung cancer patients. <i>Translational Research</i> , 2021, 233, 92-103.	5.0	14
27	Anaplastic lymphoma kinase rearrangement may increase the incidence of venous thromboembolism by increasing tissue factor expression in advanced lung adenocarcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 1307-1307.	1.7	14
28	Reduction of AZGP1 predicts poor prognosis in esophageal squamous cell carcinoma patients in Northern China. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 85-94.	2.0	12
29	Predictive significance of HMGCS2 for prognosis in resected Chinese esophageal squamous cell carcinoma patients. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2553-2560.	2.0	12
30	Increased detection of circulating tumor DNA by short fragment enrichment. <i>Translational Lung Cancer Research</i> , 2021, 10, 1501-1511.	2.8	11
31	Consistency of recommendations for the diagnosis and treatment of non-small cell lung cancer: a systematic review. <i>Translational Lung Cancer Research</i> , 2021, 10, 2715-2732.	2.8	11
32	Pathological complete response to gefitinib in a 10-year-old boy with EGFR-negative pulmonary mucoepidermoid carcinoma: a case report and literature review. <i>Clinical Respiratory Journal</i> , 2017, 11, 346-351.	1.6	10
33	Third-line treatment: A randomized, double-blind, placebo-controlled phase III ALTER-0303 study—Efficacy and safety of anlotinib treatment in patients with refractory advanced NSCLC. <i>Journal of Clinical Oncology</i> , 2017, 35, 9053-9053.	1.6	10
34	Next-generation Sequencing Identified a Novel WDPCP-ALK Fusion Sensitive to Crizotinib in Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2019, 20, e548-e551.	2.6	9
35	Cell-free DNA from cerebrospinal fluid can be used to detect the EGFR mutation status of lung adenocarcinoma patients with central nervous system metastasis. <i>Translational Lung Cancer Research</i> , 2021, 10, 914-925.	2.8	9
36	When cancer encounters COVID-19 in China: what have we suffered, experienced and learned. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 712-717.	1.3	8

#	ARTICLE	IF	CITATIONS
37	Potentially functional variants of ERAP1, PSMF1 and NCF2 in the MHC-I-related pathway predict non-small cell lung cancer survival. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2819-2833.	4.2	8
38	A novel 12-gene prognostic signature in breast cancer based on the tumor microenvironment. <i>Annals of Translational Medicine</i> , 2022, 10, 143-143.	1.7	8
39	Anlotinib for patients with small cell lung cancer and baseline liver metastases: A post hoc analysis of the ALTER 1202 trial. <i>Cancer Medicine</i> , 2022, 11, 1081-1087.	2.8	8
40	Dynamic changes of acquired T790M mutation and small cell lung cancer transformation in a patient with EGFR-mutant adenocarcinoma after first- and third-generation EGFR-TKIs: a case report. <i>Translational Lung Cancer Research</i> , 2020, 9, 139-143.	2.8	7
41	HLA loss of heterozygosity-mediated discordant responses to immune checkpoint blockade in squamous cell lung cancer with renal metastasis. <i>Immunotherapy</i> , 2021, 13, 195-200.	2.0	7
42	Safety but Limited Efficacy of Ensartinib in ROS1-Positive NSCLC: A Single-Arm, Multicenter Phase 2 Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1959-1963.	1.1	7
43	Coexistence of a novel CCNY-ALK and ATIC-ALK double-fusion in one patient with ALK-positive NSCLC and response to crizotinib: a case report. <i>Translational Lung Cancer Research</i> , 2020, 9, 2494-2499.	2.8	7
44	Novel genetic variants in KIF16B and NEDD4L in the endosome-related genes are associated with nonsmall cell lung cancer survival. <i>International Journal of Cancer</i> , 2020, 147, 392-403.	5.1	6
45	Evolution of Lung Cancer in the Context of Immunotherapy. <i>Clinical Medicine Insights: Oncology</i> , 2020, 14, 117955492097969.	1.3	6
46	Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202). <i>Frontiers of Medicine</i> , 2022, 16, 766-772.	3.4	6
47	Apatinib with etoposide capsules as a third- or further-line therapy for extensive-stage small cell lung cancer: an open-label, multicenter, single-arm phase II trial. <i>Translational Lung Cancer Research</i> , 2021, 10, 889-899.	2.8	5
48	Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (<sc>SCC</sc>): A post hoc analysis of the <sc>ALTER0303</sc> trial. <i>Thoracic Cancer</i> , 2021, 12, 2345-2351.	1.9	5
49	Effectiveness of anlotinib in patients with small cell lung cancer and pleural effusion: Subgroup analysis from a randomized, multicenter, phase II study. <i>Thoracic Cancer</i> , 2021, 12, 3039-3045.	1.9	5
50	Perioperative chemotherapy with pemetrexed and cisplatin for pulmonary large-cell neuroendocrine carcinoma: a case report and literature review. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2557-2563.	2.0	4
51	Gefitinib Represses JAK-STAT Signaling Activated by CRTC1-MAML2 Fusion in Mucoepidermoid Carcinoma Cells. <i>Current Cancer Drug Targets</i> , 2019, 19, 796-806.	1.6	4
52	Sintilimab plus anlotinib as second or further-line therapy for small cell lung cancer: An objective performance trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8516-8516.	1.6	4
53	Subgroup analysis of elderly patients (pts) in ALTER0303: Anlotinib hydrochloride as 3 rd -line and further line treatment in refractory advanced NSCLC pts from a randomized, double-blind, placebo-controlled phase III ALTER0303 trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21181-e21181.	1.6	3
54	The correlation between crizotinib efficacy and molecular heterogeneity by next-generation sequencing in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 2948-2959.	1.4	2

#	ARTICLE	IF	CITATIONS
55	PET-CT evaluation of the curative effect of crizotinib on malignant myofibroblastoma with rare mutation of ALK R401: a case report and literature review. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 1921-1927.	2.0	2
56	The benefits of etoposide capsules as maintenance therapy for patients with extensive-stage small cell lung cancer: a prospective two-stage, two-center study. <i>Journal of Thoracic Disease</i> , 2021, 13, 343-352.	1.4	2
57	Reporting quality of practice guidelines on colorectal cancer: evaluation using the RIGHT reporting checklist. <i>Annals of Translational Medicine</i> , 2021, 9, 1175-1175.	1.7	2
58	Novel genetic variants of and involved in immunoregulatory interactions are associated with non-small cell lung cancer survival. <i>American Journal of Cancer Research</i> , 2020, 10, 1770-1784.	1.4	2
59	Pharmacokinetic and bioequivalence study of new S-1 capsule in Chinese cancer patients. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 151, 105384.	4.0	1
60	MICA enhances sensitivity to cisplatin in patients with extensive small cell lung cancer via downregulation of ABCG2. <i>Oncology Letters</i> , 2020, 20, 1143-1152.	1.8	1
61	A Case of Novel Inversion Mutation of EGFR Exon 19 Leading to Primary Resistance to EGFR TKIs in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2018, 13, e97-e101.	1.1	0
62	Epidermal growth factor upregulates the expression of A20 in hepatic cells via the MEK1/MSK1/p-p65 (Ser276) signaling pathway. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 708-718.	0.0	0